They used a new and innovative technology called proteolysis targeting chimera (PROTAC) to successfully destroy RIPK1 in ...

Data from preclinical studies conducted to evaluate the activity of NKT-3964, a first-in-class, orally bioavailable CDK2-selective PROTAC degrader being developed for the potential treatment of cancer ...

Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented (SABCS), being held December 10-13, 2024, in San Antonio, Texas.

They reported an RNA aptamer-based PROTAC degrader capable of targeting ... significant antitumor efficacy in p53-R175H-driven cancer cells both in vitro and in vivo, without toxicity.

However, drug resistance often occurs when tumors shift to alternative growth pathways ... However, due to its strong cardiotoxicity, bufalin has limited translational potential. A PROTAC is a ...